Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company developing fully synthetic, constrained peptide-based therapeutics called Bicycle® molecules. These molecules combine biologic-like target specificity with small molecule pharmacokinetics and manufacturing advantages. The company’s core products include Bicycle Toxin Conjugates (BTCs), Tumor-Targeted Immune Cell Agonists (TICAs), and Radionuclide Conjugates (BRCs), primarily targeting oncology indications. Its proprietary phage display platform enables rapid discovery of candidates for diverse diseases, focusing on improved tumor penetration, selectivity, and safety.
This description was generated via AI from an annual report. Updated about 1 year ago.